Details

Autor(en) / Beteiligte

• Dotti, Adriana Zanoni
• Magro, Daniela Oliveira
• Vilela, Eduardo Garcia
• Chebli, Julio Maria Fonseca
• Chebli, Liliana Andrade
• Steinwurz, Flavio
• Argollo, Marjorie
• Carvalho, Nayara Salgado
• Parente, Jose Miguel Luz
• Lima, Murilo Moura
• Parra, Rogério Serafim
• Perin, Ramir Luan
• Flores, Cristina
• Morsoletto, Eloá Marussi
• da Costa Ferreira, Sandro
• Ludvig, Juliano Coelho
• Kaiser Junior, Roberto Luiz
• Faria, Mikaell Alexandre Gouvea
• Nicollelli, Guilherme Mattioli
• Andrade, Adriana Ribas
• Queiroz, Natalia Sousa Freitas
• Kotze, Paulo Gustavo

Titel

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study

Ist Teil von

• Crohn's & colitis 360, 2023-10, Vol.5 (4), p.otad053-otad053

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2023

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Abstract Background In real-world experience, the number of patients using vedolizumab as first-line biological therapy was low. We aimed to evaluate the effectiveness and safety of vedolizumab in mild-to-moderate Crohn’s disease (CD) biologic-naïve patients. Methods We performed a retrospective multicentric cohort study with patients who had clinical activity scores (Harvey–Bradshaw Index [HBI]) measured at baseline and weeks 12, 26, 52, as well as at the last follow-up. Clinical response was defined as a reduction ≥3 in HBI, whereas clinical remission as HBI ≤4. Mucosal healing was defined as the complete absence of ulcers in control colonoscopies. Kaplan–Meier survival analysis was used to assess the persistence with vedolizumab. Results From a total of 66 patients, 53% (35/66) reached clinical remission at week 12. This percentage increased to 69.7% (46/66) at week 26, and 78.8% (52/66) at week 52. Mucosal healing was achieved in 62.3% (33/53) of patients. Vedolizumab was well tolerated, and most adverse events were minor. During vedolizumab treatment, 3/66 patients underwent surgery. Conclusions This study demonstrates the effectiveness and safety of vedolizumab as a first-line biological agent in patients with mild-to-moderate CD. Lay Summary This study confirmed the effectiveness and safety of vedolizumab as a first-line biologic in patients with mild-to-moderate Crohn’s disease who are unresponsive to conventional therapy and biologic naïve. Graphical Abstract Graphical Abstract